🎉 M&A multiples are live!
Check it out!

Apellis Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Apellis Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Apellis Pharmaceuticals Overview

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.


Founded

2009

HQ

United States of America
Employees

710

Website

apellis.com

Financials

LTM Revenue $804M

LTM EBITDA -$137M

EV

$2.5B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Apellis Pharmaceuticals Financials

Apellis Pharmaceuticals has a last 12-month revenue of $804M and a last 12-month EBITDA of -$137M.

In the most recent fiscal year, Apellis Pharmaceuticals achieved revenue of $781M and an EBITDA of -$155M.

Apellis Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Apellis Pharmaceuticals valuation multiples based on analyst estimates

Apellis Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $397M $781M XXX XXX XXX
Gross Profit $69.8M $338M XXX XXX XXX
Gross Margin 18% 43% XXX XXX XXX
EBITDA -$495M -$155M XXX XXX XXX
EBITDA Margin -125% -20% XXX XXX XXX
Net Profit -$652M -$529M XXX XXX XXX
Net Margin -164% -68% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Apellis Pharmaceuticals Stock Performance

As of April 15, 2025, Apellis Pharmaceuticals's stock price is $19.

Apellis Pharmaceuticals has current market cap of $2.4B, and EV of $2.5B.

See Apellis Pharmaceuticals trading valuation data

Apellis Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.5B $2.4B XXX XXX XXX XXX $-1.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Apellis Pharmaceuticals Valuation Multiples

As of April 15, 2025, Apellis Pharmaceuticals has market cap of $2.4B and EV of $2.5B.

Apellis Pharmaceuticals's trades at 3.1x LTM EV/Revenue multiple, and -18.2x LTM EBITDA.

Analysts estimate Apellis Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Apellis Pharmaceuticals and 10K+ public comps

Apellis Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.5B XXX XXX XXX
EV/Revenue 3.2x XXX XXX XXX
EV/EBITDA -16.1x XXX XXX XXX
P/E -12.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -28.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Apellis Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Apellis Pharmaceuticals Valuation Multiples

Apellis Pharmaceuticals's NTM/LTM revenue growth is 13%

Apellis Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Apellis Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Apellis Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Apellis Pharmaceuticals and other 10K+ public comps

Apellis Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 97% XXX XXX XXX XXX
EBITDA Margin -20% XXX XXX XXX XXX
EBITDA Growth -69% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -7% XXX XXX XXX XXX
Revenue per Employee $1.1M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 42% XXX XXX XXX XXX
Opex to Revenue 106% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Apellis Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Apellis Pharmaceuticals M&A and Investment Activity

Apellis Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Apellis Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Apellis Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Apellis Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Apellis Pharmaceuticals

When was Apellis Pharmaceuticals founded? Apellis Pharmaceuticals was founded in 2009.
Where is Apellis Pharmaceuticals headquartered? Apellis Pharmaceuticals is headquartered in United States of America.
How many employees does Apellis Pharmaceuticals have? As of today, Apellis Pharmaceuticals has 710 employees.
Who is the CEO of Apellis Pharmaceuticals? Apellis Pharmaceuticals's CEO is Dr. Cedric Francois, M.D..
Is Apellis Pharmaceuticals publicy listed? Yes, Apellis Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Apellis Pharmaceuticals? Apellis Pharmaceuticals trades under APLS ticker.
When did Apellis Pharmaceuticals go public? Apellis Pharmaceuticals went public in 2017.
Who are competitors of Apellis Pharmaceuticals? Similar companies to Apellis Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Apellis Pharmaceuticals? Apellis Pharmaceuticals's current market cap is $2.4B
What is the current revenue of Apellis Pharmaceuticals? Apellis Pharmaceuticals's last 12-month revenue is $804M.
What is the current EBITDA of Apellis Pharmaceuticals? Apellis Pharmaceuticals's last 12-month EBITDA is -$137M.
What is the current EV/Revenue multiple of Apellis Pharmaceuticals? Current revenue multiple of Apellis Pharmaceuticals is 3.1x.
What is the current EV/EBITDA multiple of Apellis Pharmaceuticals? Current EBITDA multiple of Apellis Pharmaceuticals is -18.2x.
What is the current revenue growth of Apellis Pharmaceuticals? Apellis Pharmaceuticals revenue growth between 2023 and 2024 was 97%.
Is Apellis Pharmaceuticals profitable? Yes, Apellis Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.